Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

319.58 +60.24 (+23.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,136,181
Open 274.98
Bid (Size) 317.00 (1)
Ask (Size) 322.80 (1)
Prev. Close 259.34
Today's Range 262.85 - 321.19
52wk Range 130.78 - 299.98
Shares Outstanding 17,103,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
+40.87%
+40.87%
1 Month
+52.67%
+52.67%
3 Month
+14.76%
+14.76%
6 Month
+47.92%
+47.92%
1 Year
+134.14%
+134.14%

More News

Read More
Earnings Preview For Madrigal Pharmaceuticals
Via Benzinga
Is Madrigal Pharmaceuticals Stock a Buy?
Via The Motley Fool
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is Madrigal Pharmaceuticals Stock a Buy?
Via The Motley Fool
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
Via The Motley Fool
7 Biotech Stocks to Keep on Your Clinical Radar
Via InvestorPlace
Is Madrigal Pharmaceuticals a Millionaire Maker?
Via The Motley Fool
Is Madrigal Pharmaceuticals Stock a Buy?
Via The Motley Fool
The Best Biotech Stock to Invest $1,000 in Right Now
Via The Motley Fool
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
Via Investor's Business Daily
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Via The Motley Fool
Where Will Madrigal Pharmaceuticals Be in 3 Years?
Via The Motley Fool
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Via The Motley Fool
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Via Investor's Business Daily
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Via Investor's Business Daily
The Week Ahead: What's Next
Via Talk Markets
MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.